Peter Buchwald

List of Publications by Year
in descending order

133	4,376	117625	149698
papers	citations	34 h-index	56 g-index

157	157	157	5026
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	RNA aptamers specific for transmembrane p24 trafficking protein 6 and Clusterin for the targeted delivery of imaging reagents and RNA therapeutics to human Î² cells. Nature Communications, 2022, 13, 1815.	12.8	6
2	Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19. Frontiers in Drug Discovery, 2022, 2, .	2.8	5
3	Parallel Evaluation of Polyethylene Glycol Conformal Coating and Alginate Microencapsulation as Immunoisolation Strategies for Pancreatic Islet Transplantation. Frontiers in Bioengineering and Biotechnology, 2022, 10, .	4.1	4
4	Methylene Blue Is a Nonspecific Proteinâ€“Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19. Pharmaceuticals, 2022, 15, 621.	3.8	8
5	Drug-Integrating Amphiphilic Nanomaterial Assemblies: 1. Spatiotemporal control of cyclosporine delivery and activity using nanomicelles and nanofibrils. Journal of Controlled Release, 2021, 329, 955-970.	9.9	8
6	Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	12
7	Organoid microphysiological system preserves pancreatic islet function within 3D matrix. Science Advances, 2021, 7, .	10.3	59
8	Parallel Multi-Omics in High-Risk Subjects for the Identification of Integrated Biomarker Signatures of Type 1 Diabetes. Biomolecules, 2021, 11, 383.	4.0	17
9	Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Proteinâ€“Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. ACS Infectious Diseases, 2021, 7, 1519-1534.	3.8	77
10	Cdc42 GTPase-activating proteins (GAPs) regulate generational inheritance of cell polarity and cell shape in fission yeast. Molecular Biology of the Cell, 2021, 32, ar14.	2.1	4
11	A single unified model for fitting simple to complex receptor response data. Scientific Reports, 2020, 10, 13386.	3.3	19
12	Controlled Nutrient Delivery to Pancreatic Islets Using Polydopamine-Coated Mesoporous Silica Nanoparticles. Nano Letters, 2020, 20, 7220-7229.	9.1	16
13	Soft drugs: design principles, success stories, and future perspectives. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 645-650.	3.3	16
14	A Collagen Based Cryogel Bioscaffold that Generates Oxygen for Islet Transplantation. Advanced Functional Materials, 2020, 30, 1902463.	14.9	40
15	Islet Transplantation: A Collagen Based Cryogel Bioscaffold that Generates Oxygen for Islet Transplantation (Adv. Funct. Mater. 15/2020). Advanced Functional Materials, 2020, 30, 2070099.	14.9	1
16	The Effect of Recovery Warm-up Time Following Cold Storage on the Dynamic Glucose-stimulated Insulin Secretion of Isolated Human Islets. Cell Transplantation, 2020, 29, 096368972090827.	2.5	0
17	Methylene Blue Inhibits the SARS-CoV-2 Spikeâ€“ACE2 Protein-Protein Interactionâ€“a Mechanism that can Contribute to its Antiviral Activity Against COVID-19. Frontiers in Pharmacology, 2020, 11, 600372.	3.5	64
18	Longitudinal proteomics analysis in the immediate microenvironment of islet allografts during progression of rejection. Journal of Proteomics, 2020, 223, 103826.	2.4	9

#	Article	IF	Citations
19	A Receptor Model With Binding Affinity, Activation Efficacy, and Signal Amplification Parameters for Complex Fractional Response Versus Occupancy Data. Frontiers in Pharmacology, 2019, 10, 605.	3.5	37
20	Concentration-Dependency and Time Profile of Insulin Secretion: Dynamic Perifusion Studies With Human and Murine Islets. Frontiers in Endocrinology, 2019, 10, 680.	3.5	45
21	CD40-targeting KGYY15 peptides do not efficiently block the CD40â€“CD40L interaction. Diabetologia, 2019, 62, 2158-2160.	6.3	5
22	Feasibility of Localized Metabolomics in the Study of Pancreatic Islets and Diabetes. Metabolites, 2019, 9, 207.	2.9	9
23	In vivo imaging of type 1 diabetes immunopathology using eye-transplanted islets in NOD mice. Diabetologia, 2019, 62, 1237-1250.	6.3	20
24	A Double Fail-Safe Approach to Prevent Tumorigenesis and Select Pancreatic Î² Cells from Human Embryonic Stem Cells. Stem Cell Reports, 2019, 12, 611-623.	4.8	32
25	Local delivery of fingolimod from threeâ€dimensional scaffolds impacts islet graft efficacy and microenvironment in a murine diabetic model. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, 393-404.	2.7	29
26	Design, Synthesis, and Evaluation of Novel Immunomodulatory Small Molecules Targeting the CD40â€“CD154 Costimulatory Protein-Protein Interaction. Molecules, 2018, 23, 1153.	3.8	13
27	Glucoseâ€stimulated insulin release: Parallel perifusion studies of free and hydrogel encapsulated human pancreatic islets. Biotechnology and Bioengineering, 2018, 115, 232-245.	3.3	62
28	Toward Small-Molecule Inhibition of Proteinâ€“Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions. Current Topics in Medicinal Chemistry, 2018, 18, 674-699.	2.1	69
29	Predicting Insulin Secretion Profiles for Immunoisolating Devices with Transplanted Islets. Diabetes, 2018, 67, 27-OR.	0.6	1
30	Effect of Arginase-1 Inhibition on the Incidence of Autoimmune Diabetes in NOD Mice. Current Research in Diabetes & Obesity Journal, 2018, 5, .	0.0	4
31	Resealable, optically accessible, PDMS-free fluidic platform for ex vivo interrogation of pancreatic islets. Lab on A Chip, 2017, 17, 772-781.	6.0	52
32	Metabolomics Study of the Effects of Inflammation, Hypoxia, and High Glucose on Isolated Human Pancreatic Islets. Journal of Proteome Research, 2017, 16, 2294-2306.	3.7	35
33	A threeâ€parameter twoâ€state model of receptor function that incorporates affinity, efficacy, and signal amplification. Pharmacology Research and Perspectives, 2017, 5, e00311.	2.4	21
34	Small-Molecule Inhibitors of the CD40â€“CD40L Costimulatory Proteinâ€“Protein Interaction. Journal of Medicinal Chemistry, 2017, 60, 8906-8922.	6.4	22
35	Comprehensive Metabolomics Study To Assess Longitudinal Biochemical Changes and Potential Early Biomarkers in Nonobese Diabetic Mice That Progress to Diabetes. Journal of Proteome Research, 2017, 16, 3873-3890.	3.7	13
36	Dose-escalation study of octanoic acid in patients with essential tremor. Journal of Clinical Investigation, 2016, 126, 1451-1457.	8.2	17

#	Article	IF	Citations
37	Cell length growth patterns in fission yeast reveal a novel size control mechanism operating in late G2 phase. Biology of the Cell, 2016, 108, 259-277.	2.0	12
38	Brain-Targeting Chemical Delivery Systems and Their Cyclodextrin-Based Formulations in Light of the Contributions of Marcus E. Brewster. Journal of Pharmaceutical Sciences, 2016, 105, 2589-2600.	3.3	16
39	Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer. Breast Cancer Research and Treatment, 2016, 157, 77-90.	2.5	52
40	Fully Automated Islet Cell Counter (ICC) for the Assessment of Islet Mass, Purity, and Size Distribution by Digital Image Analysis. Cell Transplantation, 2016, 25, 1747-1761.	2.5	19
41	Biphasic decline of Î²â€cell function with age in euglycemic nonobese diabetic mice parallels diabetes onset. IUBMB Life, 2015, 67, 634-644.	3.4	8
42	Controlled Release of Dexamethasone from Organosilicone Constructs for Local Modulation of Inflammation in Islet Transplantation. Tissue Engineering - Part A, 2015, 21, 2250-2261.	3.1	31
43	Experimental evaluation and computational modeling of the effects of encapsulation on the time-profile of glucose-stimulated insulin release of pancreatic islets. BioMedical Engineering OnLine, 2015, 14, 28.	2.7	25
44	Phosphorylation-dependent inhibition of Cdc42 GEF Gef1 by 14-3-3 protein Rad24 spatially regulates Cdc42 GTPase activity and oscillatory dynamics during cell morphogenesis. Molecular Biology of the Cell, 2015, 26, 3520-3534.	2.1	40
45	Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nature Communications, 2015, 6, 7419.	12.8	149
46	TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation. Current Drug Targets, 2015, 16, 393-408.	2.1	28
47	Activity-Limiting Role of Molecular Size: Size-Dependency of Maximum Activity for P450 Inhibition as Revealed by qHTS Data. Drug Metabolism and Disposition, 2014, 42, 1785-1790.	3.3	6
48	Bilinear Model for the Sizeâ€Dependency of the CYP3A4 Inhibitory Activity of Structurally Diverse Compounds. Molecular Informatics, 2014, 33, 8-14.	2.5	2
49	Effects of representative glucocorticoids on TNFÎ±- and CD40L-induced NF-ÎºB activation in sensor cells. Steroids, 2014, 85, 36-43.	1.8	17
50	Is there a universal rule for cellular growth? - Problems in studying and interpreting this phenomenon. FEMS Yeast Research, 2014, 14, 679-682.	2.3	5
51	Smallâ€molecule modulators of the <scp>OX</scp>40â€“<scp>OX40</scp> ligand coâ€stimulatory proteinâ€“protein interaction. British Journal of Pharmacology, 2014, 171, 4955-4969.	5.4	27
52	Recent advances in the design and development of soft drugs. Die Pharmazie, 2014, 69, 403-13.	0.5	18
53	Cell length growth in fission yeast: an analysis of its bilinear character and the nature of its rate change transition. FEMS Yeast Research, 2013, 13, 635-649.	2.3	24
54	The promiscuous protein binding ability of erythrosine B studied by metachromasy (metachromasia). Journal of Molecular Recognition, 2013, 26, 181-189.	2.1	14

#	Article	IF	Citations
55	Octanoic acid in alcohol-responsive essential tremor. Neurology, 2013, 80, 933-940.	1.1	34
56	Glucose-stimulated insulin secretion in isolated pancreatic islets: Multiphysics FEM model calculations compared to results of perifusion experiments with human islets. Journal of Biomedical Science and Engineering, 2013, 06, 26-35.	0.4	7
57	Oscillatory Dynamics of Cdc42 GTPase in the Control of Polarized Growth. Science, 2012, 337, 239-243.	12.6	148
58	Exploratory computational assessment of possible binding modes for small molecule inhibitors of the CD40-CD154 co-stimulatory interaction. Die Pharmazie, 2012, 67, 374-9.	0.5	4
59	Feasibility of localized immunosuppression: 3. Preliminary evaluation of organosilicone constructs designed for sustained drug release in a cell transplant environment using dexamethasone. Die Pharmazie, 2012, 67, 394-9.	0.5	8
60	Modeling Fission-Yeast Growth Partitioning and Oscillating Cortical Cdc42 Populations. Biophysical Journal, 2011, 100, 445a.	0.5	1
61	Quantification of the Islet Product: Presentation of a Standardized Current Good Manufacturing Practices Compliant System With Minimal Variability. Transplantation, 2011, 91, 677-683.	1.0	36
62	The food colorant erythrosine is a promiscuous proteinâ€“protein interaction inhibitor. Biochemical Pharmacology, 2011, 81, 810-818.	4.4	57
63	An Open-Label, Single-Dose, Crossover Study of the Pharmacokinetics and Metabolism of Two Oral Formulations of 1-Octanol in Patients with Essential Tremor. Neurotherapeutics, 2011, 8, 753-762.	4.4	31
64	A local glucose-and oxygen concentration-based insulin secretion model for pancreatic islets. Theoretical Biology and Medical Modelling, 2011, 8, 20.	2.1	104
65	Organic dyes as small molecule proteinâ€“protein interaction inhibitors for the CD40â€“CD154 costimulatory interaction. Journal of Molecular Recognition, 2010, 23, 65-73.	2.1	9
66	Choice of Immunosuppression Influences Cytomegalovirus DNAemia in Cynomolgus Monkey (Macaca fascicularis) Islet Allograft Recipients. Cell Transplantation, 2010, 19, 1547-1561.	2.5	12
67	A simple, predictive, structure-based skin permeability model. Journal of Pharmacy and Pharmacology, 2010, 53, 1087-1098.	2.4	67
68	Direct, differential-equation-based in-vitroâ€“in-vivo correlation (IVIVC) method. Journal of Pharmacy and Pharmacology, 2010, 55, 495-504.	2.4	56
69	Synthesis and pharmacological effects of new, N-substituted soft anticholinergics based on glycopyrrolate. Journal of Pharmacy and Pharmacology, 2010, 57, 1427-1435.	2.4	17
70	Novel, cell-penetrating molecular transporters with flexible backbones and permanently charged side-chains. Journal of Pharmacy and Pharmacology, 2010, 59, 1065-1076.	2.4	13
71	Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats. Journal of Pharmacy and Pharmacology, 2010, 60, 291-297.	2.4	8
72	Smallâ€molecule proteinâ€“protein interaction inhibitors: Therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations. IUBMB Life, 2010, 62, 724-731.	3.4	115

#	Article	IF	Citations
73	Research Article: Effective and Specific Inhibition of the CD40â€“CD154 Costimulatory Interaction by a Naphthalenesulphonic Acid Derivative. Chemical Biology and Drug Design, 2010, 76, 305-313.	3.2	17
74	Molecular Organization of the Complex between the Muscarinic M3 Receptor and the Regulator of G Protein Signaling, GÎ²₅â^'RGS7. Biochemistry, 2010, 49, 4998-5006.	2.5	17
75	Feasibility of localized immunosuppression: 1. Exploratory studies with glucocorticoids in a biohybrid device designed for cell transplantation. Die Pharmazie, 2010, 65, 421-8.	0.5	19
76	Suramin inhibits the CD40â€“CD154 costimulatory interaction: A possible mechanism for immunosuppressive effects. Biochemical Pharmacology, 2009, 77, 1236-1245.	4.4	28
77	Small-molecule costimulatory blockade: organic dye inhibitors of the CD40â€“CD154 interaction. Journal of Molecular Medicine, 2009, 87, 1133-1143.	3.9	34
78	FEM-based oxygen consumption and cell viability models for avascular pancreatic islets. Theoretical Biology and Medical Modelling, 2009, 6, 5.	2.1	140
79	Quantitative Assessment of Islet Cell Products: Estimating the Accuracy of the Existing Protocol and Accounting for Islet Size Distribution. Cell Transplantation, 2009, 18, 1223-1235.	2.5	61
80	Retrometabolic drug design: Principles and recent developments. Pure and Applied Chemistry, 2008, 80, 1669-1682.	1.9	21
81	Glucocorticoid receptor binding: A biphasic dependence on molecular size as revealed by the bilinear LinBiExp model. Steroids, 2008, 73, 193-208.	1.8	39
82	The quantitative characterization of free radical sources and traps by electromigration applications. Journal of Proteomics, 2008, 70, 1317-1323.	2.4	1
83	Structural studies on the chiral selector capacity of cyclodextrin derivatives. Journal of Proteomics, 2008, 70, 1276-1282.	2.4	13
84	High-Throughput Screening for Human Galactokinase Inhibitors. Journal of Biomolecular Screening, 2008, 13, 415-423.	2.6	45
85	Stereoisomers of N-substituted soft anticholinergics and their zwitterionic metabolite based on glycopyrrolate--syntheses and pharmacological evaluations. Die Pharmazie, 2008, 63, 200-9.	0.5	7
86	Soft corticosteroids for local immunosuppression: exploring the possibility for the use of loteprednol etabonate for islet transplantation. Die Pharmazie, 2008, 63, 226-32.	0.5	14
87	A general bilinear model to describe growth or decline time profiles. Mathematical Biosciences, 2007, 205, 108-136.	1.9	44
88	Computer-aided retrometabolic drug design: soft drugs. Expert Opinion on Drug Discovery, 2007, 2, 923-933.	5.0	7
89	Brain-Targeted Delivery of Estradiol. American Journal of Drug Delivery, 2006, 4, 161-175.	0.6	11
90	Soft Quaternary Anticholinergics:Â Comprehensive Quantitative Structureâ^'Activity Relationship (QSAR) with a Linearized Biexponential (LinBiExp) Model. Journal of Medicinal Chemistry, 2006, 49, 883-891.	6.4	18

#	Article	IF	Citations
91	The time-profile of cell growth in fission yeast: model selection criteria favoring bilinear models over exponential ones. Theoretical Biology and Medical Modelling, 2006, 3, 16.	2.1	26
92	Corticosteroid Design for the Treatment of Asthma: Structural Insights and the Therapeutic Potential of Soft Corticosteroids. Current Pharmaceutical Design, 2006, 12, 3241-3260.	1.9	42
93	Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. European Respiratory Journal, 2006, 27, 511-516.	6.7	35
94	General Linearized Biexponential Model for QSAR Data Showing Bilinear-Type Distribution. Journal of Pharmaceutical Sciences, 2005, 94, 2355-2379.	3.3	33
95	Unified Pharmacogenetics-Based Parentâ€“Metabolite Pharmacokinetic Model Incorporating Acetylation Polymorphism for Talampanel in Humans. Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 377-400.	1.8	4
96	Pharmacokinetic and Pharmacodynamic Evaluations of the Zwitterionic Metabolite of a New Series of N-Substituted Soft Anticholinergics. Pharmaceutical Research, 2005, 22, 2035-2044.	3.5	10
97	QSAR Study of 2,3-Benzodiazepin-4(thi)one- and 1,2-Phthalazine-Related Negative Allosteric Modulators of the AMPA Receptor: A Structural Descriptors-Based Reassessment. QSAR and Combinatorial Science, 2005, 24, 325-331.	1.4	7
98	Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems. AAPS Journal, 2005, 7, E820-E833.	4.4	86
99	Designing Safer (Soft) Drugs by Avoiding the Formation of Toxic and Oxidative Metabolites. Molecular Biotechnology, 2004, 26, 123-132.	2.4	30
100	Soft glucocorticoid design: structural elements and physicochemical parameters determining receptor-binding affinity. Die Pharmazie, 2004, 59, 396-404.	0.5	22
101	Brain-Targeted Drug Delivery. American Journal of Drug Delivery, 2003, 1, 13-26.	0.6	53
102	Designing Safer (Soft) Drugs by Avoiding the Formation of Toxic and Oxidative Metabolites. , 2002, 186, 301-312.		4
103	Complexation Thermodynamics of Cyclodextrins in the Framework of a Molecular Size-Based Model for Nonassociative Organic Liquids That Includes a Modified Hydration-Shell Hydrogen-Bond Model for Water. Journal of Physical Chemistry B, 2002, 106, 6864-6870.	2.6	31
104	In Vitro and In Vivo Evaluations of Dihydroquinoline- and Dihydroisoquinoline-based Targetor Moieties for Brain-specific Chemical Delivery Systems. Journal of Drug Targeting, 2002, 10, 63-71.	4.4	21
105	Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease. Drug Discovery Today, 2002, 7, 766-774.	6.4	79
106	Theoretical Insights into the Formation, Structure, and Energetics of Some Cyclodextrin Complexes. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2002, 44, 9-14.	1.6	19
107	Computer-aided drug design: the role of quantitative structure-property, structure-activity and structure-metabolism relationships (QSPR, QSAR, QSMR). Drugs of the Future, 2002, 27, 577.	0.1	54
108	Physicochemical aspects of the enzymatic hydrolysis of carboxylic esters. Die Pharmazie, 2002, 57, 87-93.	0.5	20

#	Article	IF	Citations
109	DRUG TARGETING BY RETROMETABOLIC DESIGN: SOFT DRUGS AND CHEMICAL DELIVERY SYSTEMS. Journal of Receptor and Signal Transduction Research, 2001, 21, 287-310.	2.5	5
110	Drug Targeting by Retrometabolic Design. Drugs and the Pharmaceutical Sciences, 2001, , .	0.1	0
111	Receptor binding studies of soft anticholinergic agents. AAPS PharmSci, 2001, 3, 44-56.	1.3	36
112	Structure-Metabolism Relationships Steric Effects and the Enzymatic Hydrolysis of Carboxylic Esters. Mini-Reviews in Medicinal Chemistry, 2001, 1, 101-111.	2.4	33
113	Attempts of Ranking in a Series of Synthetic Nonpsychotropic Cannabinoids. SAR and QSAR in Environmental Research, 2001, 12, 113-127.	2.2	2
114	Soft drug design: General principles and recent applications. Medicinal Research Reviews, 2000, 20, 58-101.	10.5	220
115	Extended covalent solid forms of carbon dioxide with carbonâ€“oxygen single bonds. Chemical Physics Letters, 2000, 319, 645-649.	2.6	6
116	Modeling liquid properties, solvation, and hydrophobicity: A molecular size-based perspective. Journal of Computer - Aided Molecular Design, 2000, 19, 19-45.	1.0	17
117	Simple Model for Nonassociative Organic Liquids and Water. Journal of the American Chemical Society, 2000, 122, 10671-10679.	13.7	21
118	Structure-based estimation of enzymatic hydrolysis rates and its application in computer-aided retrometabolic drug design. Die Pharmazie, 2000, 55, 210-7.	0.5	13
119	The Role of Computational Techniques in Retrometabolic Drug Design Strategies. Theoretical and Computational Chemistry, 1999, , 569-618.	0.4	14
120	Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Advanced Drug Delivery Reviews, 1999, 36, 229-254.	13.7	157
121	NMR investigation and secondary structure of domains I and II of rat brain calbindin D28k (1-93). FEBS Journal, 1999, 262, 933-938.	0.2	7
122	Quantitative Structureâ^'Metabolism Relationships:Â Steric and Nonsteric Effects in the Enzymatic Hydrolysis of Noncongener Carboxylic Esters. Journal of Medicinal Chemistry, 1999, 42, 5160-5168.	6.4	74
123	Octanolâ€“water partition of nonzwitterionic peptides: Predictive power of a molecular size-based model. , 1998, 30, 86-99.		50
124	Design and evaluation of new soft anticholinergic agents. Drug Development Research, 1998, 43, 117-127.	2.9	12
125	Targeted drug delivery to the brain via phosphonate derivatives II. Anionic chemical delivery system for zidovudine (AZT). International Journal of Pharmaceutics, 1998, 166, 27-35.	5.2	29
126	Targeted drug delivery to the brain via phosphonate derivatives. International Journal of Pharmaceutics, 1998, 166, 15-26.	5.2	29

#	Article	IF	Citations
127	Molecular Size-Based Model To Describe Simple Organic Liquids. Journal of Physical Chemistry B, 1998, 102, 5715-5726.	2.6	30
128	Computer-Assisted Design of New Drugs Based on Retrometabolic Concepts. SAR and QSAR in Environmental Research, 1998, 8, 41-92.	2.2	26
129	Octanol-water partition: searching for predictive models. Current Medicinal Chemistry, 1998, 5, 353-80.	2.4	25
130	Octanol-Water Partition: Searching for Predictive Models. Current Medicinal Chemistry, 1998, 5, 353-380.	2.4	159
131	Molecular Size Based Approach To Estimate Partition Properties for Organic Solutes. Journal of Physical Chemistry B, 1997, 101, 3404-3412.	2.6	96
132	Drug targeting via retrometabolic approaches. , 1997, 76, 1-27.		54
133	Drug targeting via retrometabolic approaches. , 1997, 76, 1-27.		7